Saiba is leveraging its Cucumber Mosaic Virus virus-like particle (VLP) platform technology to develop the vaccine, according to AGC. The company said that the recombinant VLP vaccine has the potential to quickly deliver a prophylaxis for COVID-19, and also has a scalable, high-yield, large-scale production capability, the firm said.

AGC also noted that the vaccine has been engineered to enhance immune responsiveness in elderly people.

AGC to manufacture adjuvant for Novavax COVID-19 vaccine
AGC Biologics announced it is partnering with Novavax for large-scale good manufacturing practices production of critical components for Novavax's coronavirus...

AGC acquires commercial manufacturing facility
Contract development and manufacturing organization AGC Biologics has purchased a large-scale biopharmaceutical manufacturing facility in Boulder, CO.

AGC to manufacture Takara Bio's COVID-19 vaccine
In the fight against COVID-19, AGC Biologics, a contract development and manufacturing organization, is partnering with Takara Bio to manufacture plasmid...

AGC Biologics, Faron to manufacture cancer immunotherapy
Contract development and manufacturing organization AGC Biologics has formed a cancer immunotherapy partnership with Faron Pharmaceuticals.

AGC Biologics, AdaptVac partner on COVID-19 vaccine
AGC Biologics, a contract development and manufacturing organization, and AdaptVac have teamed up to develop a COVID-19 vaccine.